

Asia


Treatment at diagnosis by country

Global enrolment of Prospective patients


Region	n	%
Europe	29167	56
Asia	14988	28.8
North America	1618	3.1
Latin America	4247	8.2
Rest of World	2061	4
Total	52081	100




Treatment at diagnosis by country



Treatment at diagnosis by region



Treatment at diagnosis by cohort



Baseline characteristics

		Asia N=(14988)	World N=(52081)
Sex	Female, n (%)	6149 (41.0)	23015 (44.2)
Age at Diagnosis (Years)	mean (sd)	67.5 (12.1)	69.7 (11.5)
Age Group	<65, n (%)	5530 (36.9)	15716 (30.2)
	65-74, n (%)	4912 (32.8)	16956 (32.6)
	>=75, n (%)	4546 (30.3)	19409 (37.3)
BMI (kg/m ²)	mean (sd)	24.8 (4.2)	27.8 (5.7)
Pulse (bpm)	mean (sd)	87.6 (24.0)	90.4 (26.7)
Systolic BP (mm Hg)	mean (sd)	129.2 (19.4)	133.5 (19.8)
Diastolic BP (mm Hg)	mean (sd)	77.7 (13.5)	79.7 (12.9)
Congestive heart failure	n (%)	2989 (19.9)	10405 (20.0)
Coronary artery disease	n (%)	2743 (18.3)	11251 (21.6)
Acute coronary syndrome	n (%)	1086 (7.3)	4914 (9.5)
Carotid Occlusive Disease	n (%)	270 (1.8)	1546 (3.0)
Cirrhosis	n (%)	104 (0.7)	296 (0.6)

Baseline characteristics

		Asia N=(14988)	World N=(52081)
Diabetes	n (%)	3325 (22.2)	11550 (22.2)
History of Bleeding	n (%)	248 (1.7)	1320 (2.5)
Hypercholesterolaemia	n (%)	4201 (28.7)	20975 (41.6)
PE or DVT	n (%)	94 (0.6)	1356 (2.6)
Stroke/TIA	n (%)	1617 (10.8)	5961 (11.4)
Treatment Sector	In the private sector, n (%)	6736 (52.7)	12547 (28.5)
	In the public sector, n (%)	6049 (47.3)	31431 (71.5)

Baseline characteristics

		Asia N=(14988)	World N=(52081)
CHADS2 Score	mean (sd)	1.7 (1.1)	1.9 (1.1)
CHA2DS2-VASc Score	mean (sd)	2.9 (1.6)	3.2 (1.6)
HAS BLED Score	mean (sd)	1.3 (0.9)	1.4 (0.9)

Baseline characteristics

		Asia N=(14988)	World N=(52081)
Systemic Embolization	n (%)	62 (0.4)	336 (0.6)
Type of AF Diagnosed	New, n (%)	5650 (37.7)	23366 (44.9)
	Paroxysmal, n (%)	5441 (36.3)	14313 (27.5)
	Permanent, n (%)	1307 (8.7)	6639 (12.7)
Care Setting Speciality at Diagnosis	Persistent, n (%)	2590 (17.3)	7761 (14.9)
	Cardiology, n (%)	12661 (84.5)	34219 (65.7)
	Geriatrics, n (%)	31 (0.2)	202 (0.4)
	Internal Medicine, n (%)	1711 (11.4)	9372 (18.0)
	Neurology, n (%)	132 (0.9)	876 (1.7)
	Primary Care/General Practice, n (%)	453 (3.0)	7410 (14.2)


Main reason anticoagulant not used for patients with CHA₂DS₂-VASc ≥2 .

	Cohort 1&2	
	World (N=4137)	
	Asia (N=1358)	World (N=4137)
	n	%
Patients with CHA ₂ DS ₂ -VASc ≥2 and no AC treatment at diagnosis		
Alcohol abuse	3 (0.2)	20 (0.5)
Already taking anti-platelet drugs for other medical condition	107 (7.9)	228 (5.5)
Patient refusal	77 (5.7)	336 (8.1)
Previous bleeding event	9 (0.7)	63 (1.5)
Taking medication contraindicated or cautioned for use with VKA or AC	4 (0.3)	19 (0.5)
Other	56 (4.1)	505 (12.2)
Unknown	277 (20.4)	889 (21.5)
Physician's choice	825 (60.8)	2077 (50.2)
Physician's choice - Bleeding risk	86 (6.3)	263 (6.4)
Physician's choice - Concern over patient compliance	53 (3.9)	182 (4.4)
Physician's choice - Guideline recommendation	31 (2.3)	105 (2.5)
Physician's choice - Fall risk	13 (1.0)	197 (4.8)
Physician's choice - Low risk of stroke	120 (8.8)	326 (7.9)
Physician's choice - Other	522 (38.4)	1004 (24.3)
Total	1358 (100.0)	4137 (100.0)


Main reason anticoagulant not used for patients with CHA₂DS₂-VASc ≥2.

	Cohort 3&4&5			
	Asia		World	
	(N=2618)		(N=6117)	
	n	%	n	%
Patients with CHA ₂ DS ₂ -VASc ≥2 and no AC treatment at diagnosis				
Alcohol abuse	2	(0.1)	32	(0.5)
Already taking anti-platelet drugs for other medical condition	231	(8.8)	422	(6.9)
Patient refusal	265	(10.1)	645	(10.5)
Previous bleeding event	34	(1.3)	151	(2.5)
Taking medication contraindicated or cautioned for use with VKA or AC	11	(0.4)	63	(1.0)
Other	470	(18.0)	1326	(21.7)
Unknown	785	(30.0)	1597	(26.1)
Physician's choice	820	(31.3)	1881	(30.8)
Physician's choice - Bleeding risk	318	(12.1)	611	(10.0)
Physician's choice - Concern over patient compliance	97	(3.7)	248	(4.1)
Physician's choice - Guideline recommendation	34	(1.3)	189	(3.1)
Physician's choice - Fall risk	93	(3.6)	205	(3.4)
Physician's choice - Low risk of stroke	278	(10.6)	628	(10.3)
Total	2618	(100.0)	6117	(100.0)


Stroke risk profile: CHADS₂



Stroke risk profile: CHA₂DS₂ VASc



Stroke risk profile: HAS BLED




Treatment at diagnosis by CHA2DS2-VASc score - Asia

CHA2DS2-VASc		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
Asia	Unknown	91	71	13	122	121	5	423
	0	146	81	54	181	258	5	725
	1	562	378	150	745	536	14	2385
	2	951	576	235	900	530	31	3223
	3	999	752	224	809	456	40	3280
	4	861	628	167	646	331	34	2667
	5	470	310	81	374	149	25	1409
	6-9	276	190	55	269	72	14	876


Treatment at diagnosis by CHA₂DS₂-VASc score - World

CHA ₂ DS ₂ -VASc		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	461	227	62	286	330	14	1380
	0	325	221	111	302	443	16	1418
	1	1830	1097	479	1545	1196	66	6213
	2	3835	1960	806	2154	1261	125	10141
	3	4969	2625	817	2345	1275	164	12195
	4	4711	2352	772	2043	1028	168	11074
	5	2458	1169	375	1224	449	98	5773
	6-9	1616	831	234	872	261	73	3887

Treatment at diagnosis



Treatment at diagnosis




Treatment at diagnosis by HAS BLED score - Asia

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total	
		n	n	n	n	n	n	N	n
Asia	Unknown	1255	537	150	1095	715	22	3774	3774
	0	585	419	211	0	687	24	1926	1926
	1	1378	1276	386	1019	750	69	4878	4878
	2	860	575	180	1446	242	39	3342	3342
	3	240	153	47	409	55	11	915	915
	4-9	38	26	5	77	4	3	153	153


Treatment at diagnosis by HAS BLED score - World

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	5750	2456	843	3271	2060	147	14527
	0	2144	1242	611	0	1394	96	5487
	1	6650	3866	1303	2302	1779	254	16154
	2	4165	2225	689	3689	763	163	11694
	3	1258	599	191	1250	219	53	3570
	4-9	238	94	19	259	28	11	649

Treatment at diagnosis



Treatment at diagnosis



INR values and time in therapeutic range

Variable	Statistics	Asia (N = 4356) n %	World (N = 20205) n %
INR value, n(%)	n (missing)	17497 (2074)	157134 (8319)
	<2	10349 (59.1)	50514 (32.1)
	2-3	5570 (31.8)	81056 (51.6)
	>3	1578 (9.0)	25564 (16.3)
INR value	n (missing)	17497 (2074)	157134 (8319)
	Mean (SD)	2.0 (0.9)	2.4 (0.9)
	Median (IQR)	1.8 (1.4 to 2.3)	2.3 (1.8 to 2.8)
	Min to Max	0.8 to 18.6	0.8 to 20.0
TTR, n(%)	>=65	404 (18.4)	4751 (41.4)
	n (missing)	2192 (2164)	11485 (8720)
	<65	1788 (81.6)	6734 (58.6)
TTR	n (missing)	2192 (2164)	11485 (8720)
	Mean (SD)	35.2 (28.7)	55.2 (27.3)
	Median (IQR)	32.7 (8.3 to 56.7)	59.0 (37.0 to 76.1)
	Min to Max	0.0 to 100.0	0.0 to 100.0

Event rates during the first year of follow-up (rates per 100 person-years)

	Asia		World	
	Events	Rate (95% CI)	Events	Rate (95% CI)
Death	427	3.20 (2.91 to 3.52)	2103	4.38 (4.20 to 4.57)
Cardiovascular Death	150	1.12 (0.96 to 1.32)	789	1.64 (1.53 to 1.76)
Non-cardiovascular death	153	1.15 (0.98 to 1.34)	771	1.61 (1.50 to 1.72)
Undetermined Cause	124	0.93 (0.78 to 1.11)	543	1.13 (1.04 to 1.23)
Stroke/SE	161	1.21 (1.04 to 1.41)	650	1.36 (1.26 to 1.47)
Major Bleeding	58	0.44 (0.34 to 0.56)	407	0.85 (0.77 to 0.94)
Acute coronary syndrome	53	0.40 (0.30 to 0.52)	378	0.79 (0.71 to 0.87)
Congestive hearth failure	163	1.23 (1.05 to 1.43)	1052	2.22 (2.09 to 2.35)

Cause of death during the first year of follow-up

	Asia		World	
	n	%	n	%
Cardiovascular causes				
Congestive heart failure	59	39.3	262	33.2
Sudden or unwitnessed death	24	16.0	127	16.1
Myocardial infarction	16	10.7	89	11.3
Non-haemorrhagic stroke (Ischemic Stroke)	14	9.3	86	10.9
Non Cardiovascular causes				
Malignancy	31	20.3	233	30.2
Respiratory failure	30	19.6	142	18.4
Infection	21	13.7	81	10.5
Sepsis	15	9.8	74	9.6

Type of stroke during the first year of follow-up

	Asia		World	
	n	%	n	%
Stroke (not including systemic embolism)	155	1.03	585	1.12
Primary Ischemic	107	0.71	406	0.78
of which secondary hemorrhagic ischemic	9	0.06	22	0.04
Primary intracerebral hemorrhage	19	0.13	71	0.14
Intracerebral	10	0.07	44	0.08
Intraventricular	1	0.01	9	0.02
Subarachnoid	5	0.03	13	0.02
Undetermined	29	0.19	108	0.21

Severity of bleeding during the first year of follow-up

Outcome	Asia		World	
	n	%	n	%
Major Bleed	58	0.11	407	0.78
Non-Major Clinically Relevant	94	0.18	645	1.24
Minor	220	0.42	1167	2.24
Unknown	36	0.07	136	0.26